SIRT1 and neoplasm: In addition to a reduced tumor burden, no deaths occurred in the groups of Sirt1 K/O mice treated with cisplatin or erlotinib, but the median survival time of KRASG12D/+;Sirt1+/+ mice and the mice in each single drug treatment group was less than 198.5 days (Fig. 7F, G).